Skip to main content
Download PDF

Genomic analysis of severe COVID-19 considering or not asthma comorbidity: GWAS insights from the BQC19 cohort

BMC Genomics volume 25, Article number: 482 (2024) Cite this article

Abstract

Background

The severity of COVID-19 is influenced by various factors including the presence of respiratory diseases. Studies have indicated a potential relationship between asthma and COVID-19 severity.

Objective

This study aimed to conduct a genome-wide association study (GWAS) to identify genetic and clinical variants associated with the severity of COVID-19, both among patients with and without asthma.

Methods

We analyzed data from 2131 samples sourced from the Biobanque québécoise de la COVID-19 (BQC19), with 1499 samples from patients who tested positive for COVID-19. Among these, 1110 exhibited mild-to-moderate symptoms, 389 had severe symptoms, and 58 had asthma. We conducted a comparative analysis of clinical data from individuals in these three groups and GWAS using a logistic regression model. Phenotypic data analysis resulted in the refined covariates integrated into logistic models for genetic studies.

Results

Considering a significance threshold of 1 × 10−6, seven genetic variants were associated with severe COVID-19. These variants were located proximal to five genes: sodium voltage-gated channel alpha subunit 1 (SCN10A), desmoplakin (DSP), RP1 axonemal microtubule associated (RP1), IGF like family member 1 (IGFL1), and docking protein 5 (DOK5). The GWAS comparing individuals with severe COVID-19 with asthma to those without asthma revealed four genetic variants in transmembrane protein with EGF like and two follistatin like domains 2 (TMEFF2) and huntingtin interacting protein-1 (HIP1) genes.

Conclusion

This study provides significant insights into the genetic profiles of patients with severe forms of the disease, whether accompanied by asthma or not. These findings enhance our comprehension of the genetic factors that affect COVID-19 severity.

Key messages

  • Seven genetic variants were associated with the severe form of COVID-19;

  • Four genetic variants were associated with the severe form of COVID-19 in individuals with comorbid asthma;

  • These findings help define the genetic component of the severe form of COVID-19 in relation to asthma as a comorbidity.

Peer Review reports

Introduction

In March 2020, the World Health Organization (WHO) officially declared the outbreak of coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as a global pandemic [1]. By May 2023, this disease engendered a staggering 796 million infections worldwide, resulting in approximately 6.9 million deaths, equating to a mortality rate of 0.9% [2]. The range of COVID-19 symptoms varies from asymptomatic to fatality in severe cases. The majority of those infected with the virus experience mild symptoms such as cough, fever, headache, asthenia, anosmia, and ageusia [3]. However, certain cases require hospitalization and mechanical ventilation to prevent severe respiratory failure [4]. Hospitalized patients, advanced age, male sex [5, 6], and underlying medical conditions such as hypertension, obesity, and diabetes, exhibit strong correlations with mortality [5,6,7,8,9]. The severity of COVID-19 may be affected by other factors, such as autoimmune diseases and genetic variations, which either enhance the susceptibility to severe outcomes or protect against them [10].

Various studies have work elucidating the genetic mechanisms that influence the severity of COVID-19 and associated different loci as 3p21.31 and 9q34.2 to respiratory failure and severe complications [11,12,13]. Concerning the 9q34.2 locus, it harbors the ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) gene, which may modulate COVID-19 susceptibility and symptom severity through immunological interactions and inflammatory responses [11, 14]. Earlier research has posited that the ABO gene, jointly associated with asthma and severe COVID-19, may partly explain the association between these conditions [15]. Additionally, studies have reported a lower prevalence of asthma among COVID-19 patients compared to the general population [16, 17], suggesting potential resistance conferred by asthma against viral infection [18]. Furthermore, it has been proposed that allergic asthma may enhance immunity by inducing eosinophilia and a type 2 helper T cell (Th2) inflammatory response via the interleukin (IL)-13 pathway [19]. Further genetic investigations have suggested the involvement of the 12q24.13 locus, encoding oligo-adenylate synthetases (OAS) family, in asthma’s protective mechanisms via airway remodeling [20] and in COVID-19 [21], through mechanisms aiding in viral ribonucleic acids (RNAs) degradation and viral replication inhibition by activating latent ribonuclease [22].

The objective of this study is, firstly, to identify a genetic profile distinguishing patients with severe COVID-19 from those experiencing mild-to-moderate manifestations within the Quebecois population, and secondly, to establish a genetic profile for severe COVID-19 patients afflicted with asthma compared to those without asthma.

Methods

A schematic view of the study design is presented in Fig. 1, with a brief description of the study population and the analyses performed, including the main objectives.

Fig. 1
figure 1

Explanatory diagram of the study design and objectives (figure created with BioRender.com)

Full size image

Study population

The study participants were sourced from the Biobanque québécoise de la COVID-19 (BQC19) (https://www.quebeccovidbiobank.ca/) established in Quebec, Canada. The primary objective of this biobank is to enable the scientists to access biological materials and data to facilitate COVID-19 research. Ethical approval was granted by the Research Ethics Board of the Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean (IDs: 2022–388, 2021–026). Informed consent was obtained from all participants or their legal guardians in cases where the individual was unable to provide consent or was below 18 years of age [23].

This study involved 2131 patients aged from 2 months to 102.7 years old (Table 1). The samples and clinical data were sourced from both non-hospitalized and hospitalized individuals. All participants agreed to participate in the local clinical COVID-19 testing using SARS-CoV-2 RNA reverse transcriptase polymerase chain reaction (RT-PCR). Among these participants, 1499 tested positive for SARS-CoV-2, whereas 632 tested negative. SARS-CoV-2 PCR-negative patients were recruited as controls while patients with COVID-19 were categorized into two groups based on severity: 389 severe cases and 1110 mild-to-moderate cases. The severity of COVID-19 was classified based on WHO established criteria (Fig. 2) [24].

Table 1 Summary of the studied population’s traits
Full size table
Fig. 2
figure 2

Flowchart for COVID-19 severity criteria. Participants are categorized as experiencing a severe stage of COVID-19 based on two primary criteria: a positive COVID-19 test and the necessity for hospitalization. Additionally, in conjunction with these two criteria, participants were required to satisfy the specified conditions outlined in one of the three other sections to be considered as having a severe manifestation. The figure is generated using BioRender.com

Full size image

To identify the genetic profile of patients with severe COVID-19 and asthma, we divided patients with severe COVID-19 into two subgroups: 58 patients with asthma and 323 patients without asthma. Asthma was diagnosed based on patient interviews and medical history. However, no information regarding disease severity or sub phenotypes (e.g., atopy and airway hyperresponsiveness) was available.

Clinical data for all patients included individual characteristics (age, height, weight, sex) and medical history, with common medications such as systemic corticosteroids and angiotensin converting enzyme (ACE) inhibitors. Additionally, a physician conducted a physical examination to document COVID-19 symptoms (cough, headache, sore throat, ageusia, anosmia, rhinorrhea, dyspnea, fever, diarrhea, myalgia, and fatigue), asthma or respiratory conditions, comorbidities, and persistent COVID-19 symptoms. Blood cell counts (eosinophils, neutrophils, and lymphocytes), D-dimer and C-reactive protein (CRP) levels were measured.

Whole genome sequencing

DNA extraction and whole-genome sequencing (WGS) were performed at McGill Genome Center. DNA extraction involved treating samples with a lysis buffer, followed by extraction using the CMG-1091 DNA extraction kit (Perkin Elmer on a Chemagic MSM-I instrument). DNA concentration was determined using the Quant-iTPicoGreendsDNAAssay kit (ThermoFisher Scientific, P11495). For library preparation, a 25 μl aliquot from each sample at a concentration of 16 ng/μl was used with the DNA PCR-FreePrep Tagmentation kit (Illumina, 20,041,794). Libraries quality was validated through quantitative PCR using a DNA High Sensitivity Reagent Kit (Perkin Elmer Lab Chip GX, CLS760672). Twenty-seven libraries were combined in equimolar proportions, loaded into an Illumina S4 flow cell, and sequenced on the Illumina NovaSeq 6000 [25], using the NovaSeq 6000 S4 Reagent Kit v1.5 (Illumina,20,028,312). Data from WGS were analyzed for variant detection using the GenPipesDnaSeq pipeline [26]. The reads were aligned to the human reference genome (build GRCh38) using BWA-mem aligner [27]. Then, mapping accuracy was enhanced in proximal insertion and deletion regions using GATK IndelRealigner through the GATK [28, 29] and Picard programs (http://broadinstitute.github.io/picard/). Duplicate reads were labeled using Picard Mark Duplicates and quality scores were enhanced using the GATKBaseRecalibrator. Single nucleotide variants (SNVs) were detected using GATK Haplotype Caller in GVCF mode, which enabled efficient merging of multiple samples into a single variant file downstream. Samples within each cohort were merged using GATK-combined GVCFs and genotyped using Genotype GVCFs.

Quality control measures were performed during the alignment and genotype calling phases. Samples with a mean coverage below 30x were initially enhanced through top-up procedures and contamination estimation was performed using verifyBAMid2 [30]. Concordance assessments of genotypes and sexes were conducted to address potential sample mix-up, by comparing next-generation sequencing (NGS) data and SNP array information using NGS checkmate [31] and GATK cross-check fingerprints, as necessary. Moreover, variant counts in the samples were compared. Subsequently, quality filtering was applied to both individuals and genotypes using PLINK v2.0 (www.cog-genomics.org/plink/2.0/), which was guided by data completeness levels, and aimed to eliminate individuals with high coefficients of relationship [32]. The criteria for fulfillment included: a genotype call rate > 95%, an individual call rate surpassing 90%, a Hardy–Weinberg equilibrium (HWE) P-value > 10−4, and a minor allele frequency (MAF) of at least 0.5%. Additionally, a kinship value threshold of 0.177 (KING kinship coefficients scaled to 0.5 for duplicates) was used to detect duplicate samples and first-degree relationships between samples (including parent–child and sibling–sibling pairs). In these cases, only one individual from each pair was analyzed. Following the implementation of these primary filters, 13,185,383 variants and 2131 individuals were retained for further analyses.

Genetic analyses

Participants’ phenotypic data were compared using both group-wise analyses and comparative investigations for sex-based differences. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. Continuous variables were assessed using analysis of variance (ANOVA) or Kruskal-Wallis tests, followed by Bonferroni post hoc analysis to determine specific group differences. SPSS v28.0.1 was used for the analyses and statistical significance was set at P < 0.05. For subsequent genome-wide association study (GWAS) analyses, covariates were selected based on test results and a comprehensive literature review to select confounding variables and avoid mediating variables. Principal components reflecting genotypic diversity among participants were computed and incorporated as covariates into the analysis models. This step aims to effectively address the population stratification.

The first logistic regression analysis was conducted to compare individuals with severe COVID-19 to those with mild-to-moderate forms. This model incorporated the first 10 principal components along with age and sex as covariates. Subsequently, a logistic regression analysis was conducted to compare individuals with severe COVID-19 and asthma to those without asthma. This model incorporated as covariates the first 10 principal components, the lowest values of eosinophil counts [16, 33,34,35], and the highest values of neutrophil counts of each individuals [36,37,38]. These counts were incorporated into the model due to the frequent association of pre-existing eosinophilia with allergic asthma in individuals with asthma, and the association of non-allergic type 2 asthma with neutrophil activation [39]. Eosinopenia and neutrophilia are recognized biomarkers for severe COVID-19. Systemic corticosteroids are also included as covariate because of their frequent usage in the management of severe asthma and for treating severe COVID-19 cases as well [18].

Both models utilized PLINK v2.0 (www.cog-genomics.org/plink/2.0/) on the Digital Research Alliance of Canada’s supercomputer (alliancecan.ca). To address convergence issues, both models employed the firth-fallback option, enabling the Firth regression when logistic regression failed to converge [32]. Moreover, continuous covariates were standardized for variance normalization. A significance threshold of 1 × 10−6 was considered [40].

Results

Clinical analyses

The study involved 2131 participants, with a mean age of 60.34 years (± 20.26) and an average body mass index (BMI) of 27.66 kg/m2 (± 6.50). Sex distribution was almost equal, with 49.50% females and 50.49% males. Of these participants, 80.85% (n = 1723) were hospitalized and 19.14% (n = 408) were treated as outpatients. Among the 381 patients with severe COVID-19 and known asthma status, 15% (n = 58) had asthma (Table 1).

Table 1 highlights the significant differences between patients with severe COVID-19 and those with mild-to-moderate disease manifestations. The average age exhibited by the severe group (63.93 ± 15.98 years) is higher than that in mild-to-moderate group (58.82 ± 20.66 years). Moreover, the average BMI in the severe group (28.89 ± 7.05 kg/m2) was higher than that in mild-to-moderate group (27.83 ± 6.44 kg/m2). The severe category was predominantly male, whereas the mild-to-moderate category had a higher number of females. When assessing immune cell types, individuals in the severe COVID-19 group had an elevated neutrophil count (86.36% ± 45.66%) and lower eosinophil (1.11% ± 2.06%) and lymphocyte (13.62% ± 10.42%) counts. They also exhibited elevated CRP (146.49 ± 102.01 mg/L) and D-dimer levels (3157.68 ± 5082.00 μg/L). Moreover, the two groups experienced dyspnea during hospitalization: 90% (n = 323) of patients in the severe group and 63% (n = 518) of patients in the mild-to-moderate group. The use of ACE inhibitors was significantly higher in the severe group (37%) than that in the mild-to-moderate group (23%).

When comparing patients with severe COVID-19 with and without asthma, we observed certain differences. Specifically, the BMI was significantly higher in patients with severe COVID-19 and asthma (33.70 ± 8.49 kg/m2) in comparison to those without asthma (28.17 ± 6.37 kg/m2). Moreover, in the severe group with asthma, CRP levels were lower (113.26 ± 76.33 mg/L) in comparison to the group without asthma (154.08 ± 104.90 mg/L).

Table 2 highlights the significant sex-based differences within the mild-to-moderate and severe groups and delineates the clinical characteristics based on sex. In the mild-to-moderate COVID-19 group, male patients had a higher hospitalization rate (74%, n = 379) than female patients (63%, n = 380). The male patients had a significantly higher average BMI (28.35 ± 6.18 kg/m2) in comparison to female patients (27.40 ± 6.64 kg/m2). Moreover, 27% of male patients in the same disease group received ACE inhibitor treatment, in contrast to 20% of female patients. The biological test results demonstrated that severe COVID-19 in male patients had higher neutrophilia (87.69% ± 44.38%) compared to mild-to-moderate cases (76.92% ± 14.67%). Similarly, male patients with mild-to-moderate COVID-19 exhibited a higher incidence of lymphopenia (16.79% ± 10.42%) and elevated CRP levels (93.32 ± 73.33 mg/L) compared to females (21.08% ± 12.61% and 64.09 ± 65.22 mg/L), respectively.

Table 2 Characteristics of patients with severe COVID-19 categorized by gender
Full size table

Genetic analysis

First, individuals with mild-to-moderate COVID-19 and those with severe symptoms were compared (Fig. 3). To counteract technical biases and address population stratification, 10 principal components were included as covariates in the analyses, along with age and sex. The results indicated a significant association between seven genetic variants and severe COVID-19 (Table 3).

Fig. 3
figure 3

Manhattan plot of the genome-wide association study (GWAS) between mild-to-moderate and severe COVID-19. The GWAS results are shown on the y-axis as -log10 (P-value), and on the x-axis is the chromosomal location. The red horizontal line illustrates the genome-wide association threshold (P < 5 × 10−8) and the blue line denotes the suggestive genome-wide association threshold (P < 1 × 10−6). The Manhattan plot is generated using the qqman package in R (v4.2.1) [41]

Full size image
Table 3 Significant associations with a severe form of COVID-19
Full size table

Among these variants, three (rs6599261, rs9815891, and rs62244113) were located within sodium voltage-gated channel alpha subunit 1 (SCN10A) at locus 3p22.2, with P-values ranging from 8.595 × 10−7 to 1.431 × 10−7 (Fig. 4). Another variant was located within the RP1 axonemal microtubule-associated (RP1) at locus 8q12.1 (P-value = 4.547 × 10−7). Additionally, rs1019213 is positioned 3747 base pairs (bp) upstream of IGF like family member 1 (IGFL1) at locus 19q13.32. Another intergenic variant, rs4809972, was positioned 161,552 bp downstream of docking protein 5 (DOK5) at locus 20q13.2 (P-value = 7.774 × 10−7). Within desmoplakin (DSP) located at locus 6p24.3, the variant rs4960330 was identified (P-value =5.868 × 10−7).

Fig. 4
figure 4

Zoom at associated loci with a severe form of COVID-19. Figure shows 25 kb regions for (a) sodium voltage-gated channel alpha subunit 1 (SCN10A), (b) desmoplakin (DSP), (c) RP1 axonemal microtubule-associated (RP1) and (d) IGF like family member 1 (IGFL1) genes as well as 200 kb region for e) docking protein 5 (DOK5) gene. The genome-wide association study (GWAS) results are shown on the y-axis as -log10 (P-value), and on the x-axis is the chromosomal location in Mb. At the bottom of each are the genes found in corresponding locus according to Ensemble Database library for homo sapiens v86. The plots are generated using the locuszoomr package in R (v4.3.0)

Full size image

Subsequent GWAS was conducted between the groups with severe COVID-19 and asthma and those without asthma (Fig. 5). In addition to the 10 principal components, additional covariates included the lowest eosinophil count, highest neutrophil count, and systemic corticosteroid medication. Four genetic variants were associated. Specifically, one of the variant rs74684048 was located within the transmembrane protein with EGF like and two follistatin like domains 2 (TMEFF2) at locus 2q32.3 (P-value = 2.807 × 10−7). Three additional variants (rs807875, rs807874, and rs62478485) were detected within the huntingtin interacting protein 1 (HIP1) at locus 7q11.23, with P-values ranging from 8.953 × 10−7 to 5.860 × 10−7 (Table 4 and Fig. 6).

Fig. 5
figure 5

Manhattan plot of the genome-wide association study (GWAS) between patients with severe COVID-19 plus asthma and those without asthma. The GWAS results are shown on the y-axis as -log10 (P-value), and on the x-axis is the chromosomal location. The red horizontal line illustrates the genome-wide association threshold (P < 5 × 10−8) and the blue line indicates the suggestive genome-wide association threshold (P <  1 × 10−6). The Manhattan plot is generated using the qqman package in R (v4.2.1) [41]

Full size image
Table 4 Significant associations with a severe form of COVID-19 with asthma
Full size table
Fig. 6
figure 6

Zoom at associated loci with a severe form of COVID-19 with asthma. Figure shows 25 kb regions for (a) transmembrane protein with EGF like and two follistatin like domains 2 (TMEFF2) and (b) huntingtin interacting protein 1 (HIP1) genes. The genome-wide association study (GWAS) results are shown on the y-axis as -log10 (P-value), and on the x-axis is the chromosomal location in Mb. At the bottom of each are the genes found in corresponding locus according to Ensemble Database library for homo sapiens v86. The plots are generated using the locuszoomr package in R (v4.3.0)

Full size image

Discussion

The primary objective of this study was to conduct a comprehensive pan-genomic analysis of individuals from BQC19, a representative sample of the Quebec population. The study aimed to acquire deeper insights into the genetic and clinical aspects of severe COVID-19 with and without asthma comorbidity. To reach this goal, it is one of the very few studies to compare genomes of patients with mild-to-moderate COVID-19 to the ones with severe COVID-19, allowing to better document the genomic profile specific to the severe form of COVID-19.

Two distinct genetic profiles were identified: one for individuals with severe COVID-19, and another for those with severe COVID-19 alongside asthma. The robust findings of this study were supported by the representative population, rendering results potentially applicable to the Quebec population. This analysis revealed multiple genomic loci associated with COVID-19 severity with or without asthma comorbidity, including DSP, HIP1 and RP1 genes. These genes have been associated through genomic or proteomic analyses in previous studies [42,43,44].

Precise asthma phenotyping (based on the Global Initiative for Asthma, 2023) [45] could distinguish the protective effect of allergic asthma from the potential risk associated with severe asthma in severe COVID-19 cases. Moreover, the genetic profiles identified in this study did not encompass new COVID-19 variants, as the samples were collected and analyzed prior to this emergence. Although these findings are significant, assessing them in an independent cohort is fundamental to enhance the validity of results. Additionally, increasing the sample size of patients with asthma could enhance the statistical robustness of the study, enabling a precise analysis.

When comparing mild-to-moderate and severe COVID-19 groups, seven significant variants were identified. The most prominent signal was observed at locus 3p22.2, in which three specific variants (rs6599261, rs9815891, and rs62244113) were identified. SCN10A codes for the voltage-gated sodium channel Nav1.8. Shiers et al. showed that the ACE2 receptor, responsible for SARS-CoV-2 viral entry into host cells, is predominantly expressed in neuronal nociceptors labeled by this sodium channel [46]. This implies a potential route for the infection of nociceptors through the respiratory airways due to ACE2 expression. An elevated ACE2 expression was observed in the thoracic dorsal root ganglia, which house nociceptors responsible for lung innervation [47, 48]. This is significant because of lungs being a prime site for SARS-CoV-2 viral replication [49]. The phenotypic data complement this observation with the elevated use of ACE inhibitors in severe COVID-19 cases. This could be attributed to the potential of ACE inhibitors to increase ACE2 receptor expression, enhancing viral entry [50]. Recent studies suggested an association between SCN10A and chronic obstructive pulmonary disease (COPD) [51]. Dyspnea prominently characterizes COPD, which aligns with previous clinical observations. SCN10A is also associated with cardiovascular diseases. Previous GWAS highlighted the significance of genetic variations in SCN10A on cardiac conduction [52], a factor associated with unanticipated cardiac arrest [53]. This trait is associated with a higher susceptibility to COVID-19 [54,55,56]. Moreover, research has established a correlation between cardiac conduction aberrations and SARS-CoV-2-related complications. The systemic inflammatory response to COVID-19, referred to as the “cytokine storm”, can adversely affect cardiac function and disrupt cardiac conduction [57, 58]. The significance of SCN10A has thus been assessed in both pulmonary and cardiac disorders, in accordance with recognized risk factors for severe COVID-19.

A new variant was identified at locus 8q12.1 in the RP1 gene. A recent study highlighted the significance of RP1 in association with SARS-CoV-2 and Middle East respiratory syndrome (MERS) viruses, indicating its role in facilitating viral infections and severe disease complications [42]. However, its precise contribution to disease pathophysiology remains uncertain.

The variant rs4960330, at locus 6p24.3 within DSP, is associated with severe COVID-19. A recent investigation demonstrated elevated DSP levels in acute COVID-19 cases [43]. Another study revealed 23 DSP variants associated with idiopathic pulmonary fibrosis (IPF). Among these, rs2076295 and rs2744371, were associated with increasing DSP expression in the respiratory epithelium of IPF-affected lungs [59, 60]. Recent findings indicate that up to 11% of patients develop IPF [61] after recovery from COVID-19 acute phase. rs2076295 is also associated with interstitial lung abnormalities [60], a condition frequently observed in patients with COPD [62].

The variant rs1019213 at locus 19q13.32, is positioned 3747 bp upstream of IGFL1. Elevated IGFL1 expression is associated with poor prognosis in lung adenocarcinoma [63]. However, the correlation between COVID-19 and lung cancer remains uncertain.

We identified the final intergenic variant rs4809972 at locus 20q13.2, which was 161,552 bp downstream of DOK5. Another variant near the DOK5 gene, rs60684837, was previously associated with COVID-19 mortality in the western Indian population [64]. This gene is also associated with obesity [65] and diabetes, [66] two comorbidities recurrently identified as COVID-19 risk factors in numerous investigations [67]. Additionally, another study indicated that overexpression of DOK5 in fibroblasts contributes to the progression of IPF [68]. However, it is important to interpret these results with caution due to the distance between the variant and the nearest gene.

The second GWAS compared the genetic profiles of individuals with severe COVID-19 and asthma to those without asthma. Correlation between COVID-19 and asthma is an ongoing research subject. The relationship between asthma and COVID-19 varies across asthma phenotypes. For instance, allergic asthma appears to offer protection through the IL-13 pathway [69], whereas severe asthma appears to be associated with severe COVID-19 outcomes through the ACE2 receptor pathway [70]. Genomic investigations can help elucidate the biological nature of these relationships. This study identified two genomic regions containing four variants significantly associated with the combined phenotypes of severe COVID-19 and asthma.

The variant rs74684048, located at locus 2q32.3 within TMEFF2, is associated with a specific phenotype. TMEFF2 was genetically associated with submucosal eosinophils in bronchial brushing samples of patients with severe asthma [71]. An epigenome-wide association study revealed an association between DNA methylation of TMEFF2 and lung function [72]. Additionally, other studies indicated that methylation in the TMEFF2 promoter regions reduces its activity, potentially contributing to lung tumor development [73]. There is no direct association between TMEFF2 and COVID-19. Further research is required to understand the function of this gene in both asthma and COVID-19.

Three additional variants (rs807875, rs807874, and rs62478485) within HIP1 at locus 7q11.23 were identified. This finding corroborates results of a study by Pairo et al., which associated HIP1 with severe COVID-19 [44]. It is possible that HIP1 is involved in the endocytosis process of SARS-CoV-2, as the virus enters host cells through clathrin-induced endocytosis [74], a pathway involving HIP1 [75, 76]. Additionally, other studies have revealed elevated HIP1 expression in lung cancer, with HIP1 identified as a novel fusion partner of anaplastic lymphoma kinase [77, 78]. This indicates that HIP1 may be implicated in COVID-19 through its interaction with clathrin. However, there is no distinct association between HIP1 and asthma.

Conclusions

This study enhances our understanding of the risk factors for severe COVID-19 and highlights the significant role of genetics in determining susceptibility to this form of the disease. It delineates a specific genetic profile of severe COVID-19 compared to mild-to-moderate form and severe COVID-19 with asthma compared to severe COVID-19 without asthma. These findings have the potential to enhance preventive strategies in patients with severe COVID-19. By combining the GWAS data from this study with forthcoming data, a potential polygenetic risk score can be developed to identify individuals with a high risk of developing severe COVID-19 in relation with their asthma status. Further investigations with precise asthma phenotyping are needed to refine and fortify these findings.

Availability of data and materials

All clinical and genetic data used and results generated are available from the BQC19 via data request at https://www.bqc19.ca/en/access-data.

Abbreviations

ABO :

ABO, Alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase

ACE:

Angiotensin converting enzyme

ANOVA:

Analysis of variance

BMI:

Body mass index

BQC19:

Biobanque québécoise de la COVID-19

CRP :

C-reactive protein

COPD:

Chronic obstructive pulmonary disease

COVID-19:

Coronavirus disease 2019

DOK5 :

Docking protein 5

DSP :

Desmoplakin

GWAS:

Genome-wide association study

HIP1 :

Huntingtin interacting protein 1

HWE:

Hardy-Weinberg equilibrium

IGFL1 :

IGF like family member 1

IL:

Interleukin

IPF:

Idiopathic pulmonary fibrosis

MAF:

Minor allele frequency

MERS:

Middle East respiratory syndrome

NGS:

Next-generation sequencing

OAS:

Oligoadenylate synthetase

RNA:

Ribonucleic acid

RP1 :

RP1 axonemal microtubule-associated

RT-PCR:

Reverse transcriptase polymerase chain reaction

SARS-CoV-2:

Severe acute respiratory syndrome coronavirus 2

SCN10A :

Sodium voltage-gated channel alpha subunit 1

SNV:

Single nucleotide variant

Th2:

Type 2 helper T cell

TMEFF2 :

Transmembrane protein with EGF like and two follistatin like domains 2

WGS:

Whole-genome sequencing

WHO:

World health organization

References

  1. Pandémie de maladie à coronavirus (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 1 Apr 2023.

  2. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 30 May 2023.

  3. Clinical Care Considerations: Clinical considerations for care of children and adults with confirmed COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed 30 May 2023.

  4. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. Jama. 2020;323(22):2329–30.

    Article  PubMed  Google Scholar 

  5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, Tang C, Sang L, Liu J, Ni Z. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020;158(1):97–105.

    Article  CAS  PubMed  Google Scholar 

  8. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369.

  9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. Jama. 2020;323(20):2052–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Taz TA, Ahmed K, Paul BK, Kawsar M, Aktar N, Mahmud SH, Moni MA. Network-based identification genetic effect of SARS-CoV-2 infections to idiopathic pulmonary fibrosis (IPF) patients. Brief Bioinform. 2021;22(2):1254–66.

    Article  CAS  PubMed  Google Scholar 

  11. Group SC-G. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383(16):1522–34.

    Article  Google Scholar 

  12. Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020;587(7835):610–2.

    Article  CAS  PubMed  Google Scholar 

  13. Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams CA, Walker S, Russell CD, Malinauskas T, Wu Y, Millar J. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022;607(7917):97–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, Zhang Z, Liu L, Liu T, Liu Y. Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility. Clin Infect Dis. 2021;73(2):328–31.

    Article  CAS  PubMed  Google Scholar 

  15. Baranova A, Cao H, Chen J, Zhang F. Causal association and shared genetics between asthma and COVID-19. Front Immunol. 2022;13:705379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ferastraoaru D, Hudes G, Jerschow E, Jariwala S, Karagic M, de Vos G, Rosenstreich D, Ramesh M. Eosinophilia in asthma patients is protective against severe COVID-19 illness. J Allergy Clin Immunol: Pract. 2021;9(3):1152–62 e1153.

    CAS  PubMed  Google Scholar 

  17. Gaspar-Marques J, van Zeller M, Carreiro-Martins P, Loureiro CC. Severe asthma in the era of COVID-19: a narrative review. Pulmonology. 2022;28(1):34–43.

    Article  PubMed  Google Scholar 

  18. Hughes-Visentin A, Paul ABM. Asthma and COVID-19: what do we know now. Clin Med Insights: Circ Respir Pulm Med. 2020;14:1179548420966242.

    PubMed  Google Scholar 

  19. Ramakrishnan RK, Al Heialy S, Hamid Q. Implications of preexisting asthma on COVID-19 pathogenesis. Am J Phys Lung Cell Mol Phys. 2021;320(5):L880–91.

    CAS  Google Scholar 

  20. Almoguera B, Vazquez L, Mentch F, Connolly J, Pacheco JA, Sundaresan AS, Peissig PL, Linneman JG, McCarty CA, Crosslin D. Identification of four novel loci in asthma in European American and African American populations. Am J Respir Crit Care Med. 2017;195(4):456–63.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Prasad K, Khatoon F, Rashid S, Ali N, AlAsmari AF, Ahmed MZ, Alqahtani AS, Alqahtani MS, Kumar V. Targeting hub genes and pathways of innate immune response in COVID-19: a network biology perspective. Int J Biol Macromol. 2020;163:1–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Choi UY, Kang J-S, Hwang YS, Kim Y-J. Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases. Exp Mol Med. 2015;47(3):e144–e144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Tremblay K, Rousseau S, Ma’n HZ, Auld D, Chassé M, Coderre D, Falcone EL, Gauthier N, Grandvaux N, Gros-Louis F. The Biobanque québécoise de la COVID-19 (BQC19)—a cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS One. 2021;16(5):e0245031.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Clinical management of COVID-19: Living guideline, 13 January 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.1. Accessed 1 Apr 2023.

  25. Modi A, Vai S, Caramelli D, Lari M. The Illumina sequencing protocol and the NovaSeq 6000 system. In: Bacterial Pangenomics: Methods and Protocols. Springer; 2021. p. 15–42.

    Chapter  Google Scholar 

  26. Bourgey M, Dali R, Eveleigh R, Chen KC, Letourneau L, Fillon J, Michaud M, Caron M, Sandoval J, Lefebvre F. GenPipes: an open-source framework for distributed and scalable genomic analyses. Gigascience. 2019;8(6):giz037.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:1303.3997v2, 2013.

  28. Van der Auwera GA, O’Connor BD. Genomics in the cloud: using Docker, GATK, and WDL in Terra. O’Reilly Media; 2020.

    Google Scholar 

  29. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhang F, Flickinger M, SAG T, Abecasis GR, Scott LJ, SA MC, Pato CN, Boehnke M, Kang HM, Consortium IPG. Ancestry-agnostic estimation of DNA sample contamination from sequence reads. Genome Res. 2020;30(2):185–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lee S, Lee S, Ouellette S, Park W-Y, Lee EA, Park PJ. NGSCheckMate: software for validating sample identity in next-generation sequencing studies within and across data types. Nucleic Acids Res. 2017;45(11):e103–e103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(1):s13742-13015-10047–3748.

    Article  Google Scholar 

  33. Roca E, Ventura L, Zattra CM, Lombardi C. EOSINOPENIA: an early, effective and relevant COVID-19 biomarker? QJM: Int J Med. 2021;114(1):68–9.

    Article  CAS  Google Scholar 

  34. Lombardi C, Bagnasco D, Passalacqua G. COVID-19, eosinophils, and biologicals for severe asthma. Front Allergy. 2022;3.

  35. Saidani A, Abid S, Hamza Z, Bougherriou A, Msaad S, Bahloul N. L’éosinopénie est-elle un facteur de mauvais pronostic au cours d’une infection au COVID-19? Rev Mal Respir Actual. 2022;14(1):145.

    Google Scholar 

  36. Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Baßler K, Schultze JL, Aschenbrenner AC. Neutrophils in COVID-19. Front Immunol. 2021;12:652470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wang J, Li Q, Yin Y, Zhang Y, Cao Y, Lin X, Huang L, Hoffmann D, Lu M, Qiu Y. Excessive neutrophils and neutrophil extracellular traps in COVID-19. Front Immunol. 2020;11:2063.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, Feng J, Jia Q, Song Q, Zhu B. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci. 2020;7:157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biologic significance. Am J Respir Crit Care Med. 2000;161(4):1185–90.

    Article  CAS  PubMed  Google Scholar 

  40. Margaritte-Jeannin P, Budu-Aggrey A, Ege M, Madore AM, Linhard C, Mohamdi H, von Mutius E, Granell R, Demenais F, Laprise C. Identification of OCA2 as a novel locus for the co-morbidity of asthma-plus-eczema. Clin Exp Allergy. 2022;52(1):70–81.

    Article  CAS  PubMed  Google Scholar 

  41. Turner S. Qqman: an R package for visualizing GWAS results using QQ and Manhattan plots. J Open Source Softw. 2018;3(25):731.

    Article  Google Scholar 

  42. Maldonado LL, Bertelli AM, Kamenetzky L. Molecular features similarities between SARS-CoV-2, SARS, MERS and key human genes could favour the viral infections and trigger collateral effects. Sci Rep. 2021;11(1):4108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ward KE, Steadman L, Karim AR, Reynolds GM, Pugh M, Chua W, Faustini SE, Veenith T, Thwaites RS, Openshaw PJ. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection. Clin Exp Immunol. 2023;213(2):243–51.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature. 2023:1–15.

  45. Global Initiative for Asthma: 2023 GINA Report, Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf. Accessed 1 Sept 2023.

  46. Shiers S, Ray PR, Wangzhou A, Sankaranarayanan I, Tatsui CE, Rhines LD, Li Y, Uhelski ML, Dougherty PM, Price TJ. ACE2 and SCARF expression in human DRG nociceptors: implications for SARS-CoV-2 virus neurological effects. Pain. 2020;161(11):2494.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kummer W, Fischer A, Kurkowski R, Heym C. The sensory and sympathetic innervation of guinea-pig lung and trachea as studied by retrograde neuronal tracing and double-labelling immunohistochemistry. Neuroscience. 1992;49(3):715–37.

    Article  CAS  PubMed  Google Scholar 

  48. Springall DR, Cadieux A, Oliveira H, Su H, Royston D, Polak JM. Retrograde tracing shows that CGRP-immunoreactive nerves of rat trachea and lung originate from vagal and dorsal root ganglia. J Auton Nerv Syst. 1987;20(2):155–66.

    Article  CAS  PubMed  Google Scholar 

  49. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.

    Article  CAS  PubMed  Google Scholar 

  51. Kang J, Kim KT, Lee J-H, Kim EK, Kim T-H, Yoo KH, Lee JS, Kim WJ, Kim JH, Oh Y-M. Predicting treatable traits for long-acting bronchodilators in patients with stable COPD. Int J Chron Obstruct Pulmon Dis. 2017;114:3557–65.

    Article  Google Scholar 

  52. Chambers JC, Zhao J, Terracciano CM, Bezzina CR, Zhang W, Kaba R, Navaratnarajah M, Lotlikar A, Sehmi JS, Kooner MK. Genetic variation in SCN10A influences cardiac conduction. Nat Genet. 2010;42(2):149–52.

    Article  CAS  PubMed  Google Scholar 

  53. Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud J-B, Simonet F, Verkerk AO, Schwartz PJ, Crotti L, Dagradi F. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013;45(9):1044–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Bansal A, Kumar A, Patel D, Puri R, Kalra A, Kapadia SR, Reed GW. Meta-analysis comparing outcomes in patients with and without cardiac injury and coronavirus disease 2019 (COVID 19). Am J Cardiol. 2021;141:140–6.

    Article  CAS  PubMed  Google Scholar 

  55. Li J-W, Han T-W, Woodward M, Anderson CS, Zhou H, Chen Y-D, Neal B. The impact of 2019 novel coronavirus on heart injury: a systematic review and meta-analysis. Prog Cardiovasc Dis. 2020;63(4):518–24.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Vasudeva R, Challa A, Al Rifai M, Polana T, Duran B, Vindhyal M, et al. Prevalence of cardiovascular diseases in COVID-19 related mortality in the United States. Prog Cardiovasc Dis. 2022;74.

  57. Zimmermann P, Aberer F, Braun M, Sourij H, Moser O. The arrhythmogenic face of COVID-19: Brugada ECG pattern in SARS-CoV-2 infection. J Cardiovas Dev Dis. 2022;9(4):96.

    CAS  Google Scholar 

  58. Burhan E, Mubarak F, Adilah SASU, Sari CYI, Ismail E, Astuti P, et al. Association between cardiovascular diseases and COVID-19 pneumonia outcome in Indonesia: a multi-center cohort study. Front Med. 2023;10.

  59. Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK, Steele MP, Loyd JE, Crapo JD, Silverman EK. Desmoplakin variants are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;193(10):1151–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR, Dupuis J, Xu H. Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(11):1402–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Stewart I, Jacob J, George PM, Molyneaux PL, Porter JC, Allen RJ, Aslani S, Baillie JK, Barratt SL, Beirne P. Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post–COVID-19 study. Am J Respir Crit Care Med. 2023;207(6):693–703.

    Article  PubMed  Google Scholar 

  62. Liu Y, Tang J, Sun Y. Impact of interstitial lung abnormalities on disease expression and outcomes in COPD or emphysema: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease; 2023. p. 189–206.

    Google Scholar 

  63. Wang Z, Liang X, Wang X, Yu Q. Elevated expression of IGFL1 indicates unfavorable prognosis in lung adenocarcinoma through promotion of cell proliferation and inhibition of apoptosis. Pol J Pathol. 2021;72(4):283–95.

    Article  PubMed  Google Scholar 

  64. Pandit R, Singh I, Ansari A, Raval J, Patel Z, Dixit R, Shah P, Upadhyay K, Chauhan N, Desai K, et al. First report on genome wide association study in western Indian population reveals host genetic factors for COVID-19 severity and outcome. Genomics. 2022;114(4):110399.

    Article  CAS  PubMed  Google Scholar 

  65. Saini S, Walia GK, Sachdeva MP, Gupta V. Genetics of obesity and its measures in India. J Genet. 2018;97(4):1047–71.

    Article  PubMed  Google Scholar 

  66. Tabassum R, Mahajan A, Chauhan G, Dwivedi OP, Ghosh S, Tandon N, Bharadwaj D. Evaluation of DOK5 as a susceptibility gene for type 2 diabetes and obesity in north Indian population. BMC Med Genet. 2010;11(1):1–7.

    Article  Google Scholar 

  67. Escobedo-de la Peña J, Rascón-Pacheco RA, de Jesús A-MI, González-Figueroa E, Fernández-Gárate JE, Medina-Gómez OS, Borja-Bustamante P, Santillán-Oropeza JA. Borja-Aburto VH: hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico. Arch Med Res. 2021;52(4):443–9.

    Article  Google Scholar 

  68. Ghandikota S, Sharma M, Ediga HH, Madala SK, Jegga AG. Consensus gene co-expression network analysis identifies novel genes associated with severity of fibrotic lung disease. Int J Mol Sci. 2022;23(10):5447.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Morrison CB, Edwards CE, Shaffer KM, Araba KC, Wykoff JA, Williams DR, Asakura T, Dang H, Morton LC, Gilmore RC. SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13. Proc Natl Acad Sci. 2022;119(16):e2119680119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. López-Tiro JJ, Contreras-Contreras EA, Cruz-Arellanes NN, Camargo-Pirrón MA, Cabrera-Buendía EO, Ramírez-Pérez GI, Vega-Acevedo G. Asthma and COVID-19. Rev Alerg Mex. 2022;69:15–23.

    Article  Google Scholar 

  71. Wilson SJ, Ward JA, Sousa AR, Corfield J, Bansal AT, De Meulder B, Lefaudeux D, Auffray C, Loza MJ, Baribaud F. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. Eur Respir J. 2016;48(5):1307–19.

    Article  CAS  PubMed  Google Scholar 

  72. Bolund A, Starnawska A, Miller MR, Schlünssen V, Backer V, Børglum AD, Christensen K, Tan Q, Christiansen L, Sigsgaard T. Lung function discordance in monozygotic twins and associated differences in blood DNA methylation. Clin Epigenetics. 2017;9(1):1–13.

    Article  Google Scholar 

  73. Lee SM, Park JY, Kim DS. Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer. Mol Cells. 2012;34:171–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Bayati A, Kumar R, Francis V, McPherson PS. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem. 2021;296.

  75. Legendre-Guillemin V, Metzler M, Charbonneau M, Gan L, Chopra V, Philie J, Hayden MR, McPherson PS. HIP1 and HIP12 display differential binding to F-actin, AP2, and clathrin: identification of a novel interaction with clathrin light chain. J Biol Chem. 2002;277(22):19897–904.

    Article  CAS  PubMed  Google Scholar 

  76. Metzler M, Legendre-Guillemin V, Gan L, Chopra V, Kwok A, McPherson PS, Hayden MR. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem. 2001;276(42):39271–6.

    Article  CAS  PubMed  Google Scholar 

  77. Ou S-HI, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, Ross JS, Stephens PJ, Miller VA. Identification of a novel HIP1-ALK fusion variant in non–small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J Thorac Oncol. 2014;9(12):1821–5.

    Article  CAS  PubMed  Google Scholar 

  78. Hong M, Kim RN, Song J-Y, Choi S-J, Oh E, Lira ME, Mao M, Takeuchi K, Han J, Kim J. HIP1–ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol. 2014;9(3):419–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Authors are grateful to all participants for their essential and valuable contribution.

Funding

The BQC19 received funding from the Public Health Agency of Canada, Génome Québec and Fonds de recherche du Québec – santé (FRQS) (grant number: 2021-HQ-000051).

Author information

Authors and Affiliations

  1. Centre intersectoriel en santé durable, Université du Québec à Chicoutimi, Saguenay, Québec, G7H 2B1, Canada

    Omayma Amri, Anne-Marie Madore, Anne-Marie Boucher-Lafleur & Catherine Laprise

  2. Département des sciences fondamentales, Université du Québec à Chicoutimi, Saguenay, Québec, G7H 2B1, Canada

    Omayma Amri, Anne-Marie Madore, Anne-Marie Boucher-Lafleur & Catherine Laprise

  3. Centre de recherche du Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean, Saguenay, Québec, G7H 7K9, Canada

    Catherine Laprise

Authors
  1. Omayma Amri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne-Marie Madore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne-Marie Boucher-Lafleur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catherine Laprise
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OA: Data curation, formal analysis, visualisation and writing of the original draft. AMM: Methodology, review and editing of the manuscript. AMBL: Review and editing of the manuscript. CL: Conceptualization, investigation (Saguenay–Lac-Saint-Jean site), funding acquisition, project administration, ressources, supervision, writing, reviewing and edition.

Authors’ information

Catherine Laprise is part of the Quebec Respiratory Health Network (RHN; https://rsr-qc.ca/en/), investigator of the CHILD Study, director of the Centre intersectoriel en santé durable of the Université du Québec à Chicoutimi (UQAC) and chairholder of the Canada Research Chair in the Genomics of Asthma and Allergic Diseases (https://www.chairs-chaires.gc.ca/), and co-chairholder of the Chaire de recherche du Québec en santé durable (https://chairesantedurable.ca/).

Corresponding author

Correspondence to Catherine Laprise.

Ethics declarations

Ethic approval and consent to participate

Ethical approval was granted by the Research Ethics Board of the Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean (IDs: 2022–388, 2021–026). Informed consent was obtained from all participants or their legal guardians in cases where the individual was unable to provide consent or was below 18 years of age.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amri, O., Madore, AM., Boucher-Lafleur, AM. et al. Genomic analysis of severe COVID-19 considering or not asthma comorbidity: GWAS insights from the BQC19 cohort. BMC Genomics 25, 482 (2024). https://doi.org/10.1186/s12864-024-10342-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12864-024-10342-x

Keywords

BMC Genomics

ISSN: 1471-2164

Contact us